Pressemitteilung vom 11.05.2020 Nachricht vom 11.05.2020


EURD-Liste Rev. 91

  • 5 fluorouracil / salicylic acid
  • aceclofenac
  • acemetacin
  • acetylsalicylic acid
  • alfacalcido
  • amfepramone
  • amorolfine
  • anagrelide
  • arsenic trioxide
  • atenolol / chlortalidone
  • azacitidine
  • benserazide / levodopa
  • benzylpenicillin
  • betaxolol
  • bethanechol
  • biperiden
  • busulfan
  • butoconazole
  • captopril
  • carbamazepine
  • carteolol
  • ce (conjugated estrogens) / mpa (medroxyprogesterone acetate)
  • celiprolol
  • choriogonadotropin alpha
  • cinacalcet
  • cinolazepam
  • clenbuterol
  • clobazam
  • cyproheptadine
  • cytarabine
  • daptomycin
  • denosumab (indicated for osteoporosis and for bone loss associated with hormone ablation in prostate cancer)
  • desflurane
  • dexamfetamine
  • cyanocobalamin / diclofenac / pyridoxine / thiamine
  • dimetindene / phenylephrine
  • econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide
  • epinephrine
  • epinephrine / lidocaine
  • erythromycin / tretinoin
  • etravirine
  • felodipine
  • finasteride
  • flucloxacillin
  • fosphenytoin
  • glyceryl trinitrate
  • granisetron (other formulations except for transdermal patch)
  • hypericum perforatum L., herba
  • ifosfamide
  • insulin aspart
  • insulin lispro
  • iodixanol
  • iohexol
  • iomeprol
  • iopromide
  • ipratropium
  • ipratropium / salbutamol
  • isoflurane
  • ketobemidone
  • labetalol
  • lercanidipine
  • lidocaine
  • lidocaine / tetracaine
  • carrageenin / titanium dioxide / zinc oxide, carrageenin / lidocaine / titanium dioxide / zinc oxide, titanium dioxide / zinc oxide / tetracaine hydrochloride
  • lidocaine hydrochloride / neomycin sulfate / polymyxin b
  • linezolid
  • lomustine
  • lysine acetylsalicylate
  • mequitazine
  • metamizole
  • metamizole salicylate / triacetonamine 4-toluene sulfonate
  • moxonidine
  • niclosamide
  • niflumic acid
  • nifuroxazide
  • octocog alpha
  • oxcarbazepine
  • panitumumab
  • dicyclomine hydrochloride / paracetamol
  • paricalcitol
  • patent blue V sodium
  • pelargonium sidoides dc and/or pelargonium reniforme curt. / radix
  • pethidine
  • ascorbic acid / paracetamol / pheniramine maleate
  • pheniramine maleate / tetryzoline hydrochloride
  • phenobarbital
  • phenytoin
  • piperacillin / tazobactam
  • poractant alpha
  • ritonavir
  • rivaroxaban
  • silver sulfadiazine
  • sodium iodide (123i)
  • sotalol
  • technetium (99mtc) macrosalb
  • telbivudine
  • tenecteplase
  • terbinafine
  • terizidone
  • thalidomide
  • trabectedin
  • verapamil
  • vernakalant hydrochloride
  • xylometazoline
  • zoledronic acid (indicated for cancer and fractures)
  • indium (111In) pentetreotide
  • dapagliflozin
  • crizotinib
  • vortioxetine
  • alemtuzumab
  • bedaquiline
  • clindamycin phosphate / tretinoin
  • triamcinolone (tablets and injectables)
  • human plasma protease C1 inhibitor (nationally authorised products)
  • cholic acid (oxosteroid-reductase or hydroxy-steroid dehydrogenase deficiency indication)
  • fluocinolone acetonide (intravitreal implant in applicator)
  • modafinil
  • insulin degludec / liraglutide
  • acetylsalicylic acid / bisoprolol
  • misoprostol (gastrointestinal indication)
  • sofosbuvir / ledipasvir
  • dulaglutide
  • naloxegol
  • hydrocortisone (except for products indicated in adrenal insufficiency in a modified release tablet formulation)
  • benzoyl peroxide hydrous / potassium hydroxyquinoline sulphate
  • ciclosporin (topical use)
  • naltrexone / bupropion
  • tobramycin (nebuliser solution) (centrally authorised product only)
  • raltegravir
  • netupitant / palonosetron
  • ceftolozane / tazobactam
  • idebenone (centrally authorised products)
  • ferric citrate coordination complex
  • isavuconazole
  • mepolizumab
  • dexamethasone (centrally authorised product indicated in symptomatic multiple myeloma)
  • erythromycin / isotretinoin, isotretinoin (topical formulations)
  • pitolisant
  • eluxadoline
  • glycopyrronium (indicated for the treatment of severe siallorhea)
  • lisinopril, lisinopril / hydrochlorothiazide
  • allergen for therapy: Dermatophagoides pteronyssinus / Dermatophagoides farina (oromucosal use, products authorised via mutually recognition procedure and decentralised procedure)
  • budesonide / formoterol
  • chenodeoxycholic acid (inborn error in primary bile acid synthesis, xanthomatosi - centrally authorised products only)
  • cariprazine
  • ribociclib
  • avelumab
  • trientine
  • dupilumab
  • darunavir / cobicistat / emtricitabine / tenofovir alafenamide
  • ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus), ibuprofen / caffeine
  • niraparib
  • ocrelizumab
  • semaglutide
  • sodium zirconium cyclosilicate
  • darvadstrocel
  • velmanase alfa
  • brexpiprazole
  • tildrakizumab
  • abemaciclib
  • galcanezumab
  • mogamulizumab
  • naldemedine
  • lusutrombopag
  • dacomitinib
  • fremanezumab
  • infliximab
  • lorlatinib
  • risankizumab
  • cemiplimab
  • ethanol extracts of: Iberis amara L., planta tota recens / Angelica archangelica L., radix / Matricaria recutita L., flos / Carum carvi L., fructus / Silybum marianum (L.) Gaertn., fructus / Melissa officinalis L., folium / Mentha piperita L., folium / Chelidonium majus L., herba / Glycyrrhiza glabra L., radix
  • poliovirus type 1 / poliovirus type 2 / poliovirus type 3 vaccine (oral, live, attenuated),
    poliovirus type 1 / poliovirus type 3 vaccine (oral, live, attenuated),
    poliovirus type 1 (oral, live, attenuated) vaccine,
    poliovirus type 2 (oral, live, attenuated) vaccine,
    poliovirus type 3 (oral, live, attenuated) vaccine
  • rubidium chloride RB-82
  • allergen for therapy: betula verrucosa (sublingual tablet) -authorised via decentralised procedure
  • remdesivir
  • bempedoic acid, bempedoic acid / ezetimibe
  • crisaborole
  • darolutamide
Zurück zur Übersicht

Rechtliche Hinweise

Der BPI Wirkstoff-Alert wird mit größter Sorgfalt zusammengestellt.
Der BPI e.V. haftet jedoch nicht für Unrichtigkeiten oder Unvollständigkeiten im Zusammenhang mit den bereitgestellten Inhalten. Dies gilt im Besonderen auch für eigene unternehmerische Entscheidungen, die auf Grundlage der Informationen des BPI Wirkstoff-Alerts getroffen werden.